rurioctocog alfa pegol

Rurioctocog alfa pegol is a pegylated recombinant human coagulation factor VIII (FVIII) used for the treatment and prophylaxis of bleeding in patients with hemophilia A (congenital factor VIII deficiency), typically in those aged 12 years and above. It is produced by recombinant DNA technology using a Chinese hamster ovary cell line, followed by covalent conjugation with polyethylene glycol (PEG) to extend its plasma half-life. The drug works by replacing the missing or defective FVIII in hemophilia A patients, thereby restoring normal blood clotting function and reducing bleeding episodes. Rurioctocog alfa pegol has demonstrated efficacy both as on-demand therapy for acute bleeds and as prophylactic treatment to prevent bleeding events. It was first approved by the European Commission in January 2018[1][5][6]. The product is marketed under brand names such as Adynovi and Adynovate.

Brand names

AdynoviAdynovate

Other names

PEGylated recombinant human factor VIIIPEGylated recombinant human FVIII